GeneChem is a private equity general partner firm.
Akebia Therapeutics raised $41m in a Series C round, backed by Norvatis Venture Funds and Kearny Venture Partners among others.
Venture capital-backed Ambit Biosciences Corp., has priced its IPO on NASDAQ at $8.00 per share and is expecting to raise $65m.
Venture-backed MethylGene proposes to recincorporate under a new parent organization, which will imply listing shares on NASDAQ.
Read more news concerning GeneChem
A sampling of GeneChem portfolio companies:
View all of the investments in their portfolio
Registration is fast, free and easy
Already a member?